SK41593A3 - Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds - Google Patents

Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds Download PDF

Info

Publication number
SK41593A3
SK41593A3 SK415-93A SK41593A SK41593A3 SK 41593 A3 SK41593 A3 SK 41593A3 SK 41593 A SK41593 A SK 41593A SK 41593 A3 SK41593 A3 SK 41593A3
Authority
SK
Slovakia
Prior art keywords
treatment
plasminogen activator
corneal
activator inhibitors
pai
Prior art date
Application number
SK415-93A
Other languages
English (en)
Slovak (sk)
Inventor
Eckhard Schuler
Jurgen Romisch
Eric-Paul Paques
Gerhard Dickneite
Original Assignee
Behringwerke Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke Ag filed Critical Behringwerke Ag
Publication of SK41593A3 publication Critical patent/SK41593A3/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SK415-93A 1992-04-30 1993-04-28 Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds SK41593A3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4214215A DE4214215A1 (de) 1992-04-30 1992-04-30 Verwendung von inhibitoren von plasminogenaktivatoren zur behandlung von entzuendungen

Publications (1)

Publication Number Publication Date
SK41593A3 true SK41593A3 (en) 1993-11-10

Family

ID=6457814

Family Applications (1)

Application Number Title Priority Date Filing Date
SK415-93A SK41593A3 (en) 1992-04-30 1993-04-28 Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds

Country Status (16)

Country Link
EP (1) EP0567816A1 (xx)
JP (1) JPH069425A (xx)
KR (1) KR930021179A (xx)
CN (1) CN1080873A (xx)
AU (1) AU3822993A (xx)
CA (1) CA2095207A1 (xx)
CZ (1) CZ76893A3 (xx)
DE (1) DE4214215A1 (xx)
HU (1) HUT65755A (xx)
IL (1) IL105521A0 (xx)
MX (1) MX9302519A (xx)
NO (1) NO931561L (xx)
PL (1) PL298748A1 (xx)
SK (1) SK41593A3 (xx)
UY (1) UY23572A1 (xx)
ZA (1) ZA933023B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515009B1 (en) 1991-09-27 2003-02-04 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5811447A (en) 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5468505A (en) * 1992-02-28 1995-11-21 Board Of Regents, The University Of Texas System Local delivery of fibrinolysis enhancing agents
GB2271507A (en) * 1992-09-04 1994-04-20 Summit Technology Ireland Bv Compositions containing plasmin activity inhibitors
US5886026A (en) * 1993-07-19 1999-03-23 Angiotech Pharmaceuticals Inc. Anti-angiogenic compositions and methods of use
NZ511762A (en) * 1993-07-19 2003-09-26 Univ British Columbia Anti-angiogenic compositions and methods of use
US6558798B2 (en) 1995-02-22 2003-05-06 Scimed Life Systems, Inc. Hydrophilic coating and substrates coated therewith having enhanced durability and lubricity
US5939525A (en) * 1995-03-27 1999-08-17 Viron Therapeutics, Inc. Methods of treating inflammation and compositions therefor
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6495579B1 (en) 1996-12-02 2002-12-17 Angiotech Pharmaceuticals, Inc. Method for treating multiple sclerosis
US7208010B2 (en) 2000-10-16 2007-04-24 Conor Medsystems, Inc. Expandable medical device for delivery of beneficial agent
US20040254635A1 (en) 1998-03-30 2004-12-16 Shanley John F. Expandable medical device for delivery of beneficial agent
US6241762B1 (en) 1998-03-30 2001-06-05 Conor Medsystems, Inc. Expandable medical device with ductile hinges
WO1999049887A1 (en) * 1998-04-01 1999-10-07 Biotech Australia Pty. Limited Use of protease inhibitors for treating skin wounds
US6293967B1 (en) 1998-10-29 2001-09-25 Conor Medsystems, Inc. Expandable medical device with ductile hinges
US6120847A (en) * 1999-01-08 2000-09-19 Scimed Life Systems, Inc. Surface treatment method for stent coating
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
ATE254471T1 (de) 1999-04-29 2003-12-15 Ista Pharmaceuticals Inc Verwendung eines bestimmten hyaluronidases zur entfernung von hornhautnarbengewebe, trübung und schleier
US6156373A (en) * 1999-05-03 2000-12-05 Scimed Life Systems, Inc. Medical device coating methods and devices
US6258121B1 (en) 1999-07-02 2001-07-10 Scimed Life Systems, Inc. Stent coating
JP3690720B2 (ja) 1999-09-14 2005-08-31 インターナショナル・ビジネス・マシーンズ・コーポレーション クライアントサーバーシステム、オブジェクトのプール方法および記憶媒体
DE60020727T2 (de) 1999-10-27 2006-05-04 Robert London Zhong Zusammensetzung zur vorbeugung und behandlung von transplantatabstossung
JP2001247458A (ja) * 2000-03-08 2001-09-11 Hamari Chemicals Ltd トラネキサム酸亜鉛化合物を含む糖尿病治療剤
EP1365798B1 (en) 2000-09-29 2009-12-30 Viron Therapeutics, Inc. Use of serp-1 in combination with an immunosuppressant for treating arthritis
US6764507B2 (en) 2000-10-16 2004-07-20 Conor Medsystems, Inc. Expandable medical device with improved spatial distribution
ATE387169T1 (de) 2000-10-16 2008-03-15 Conor Medsystems Inc Expandierbare medizinische vorrichtung zum zuführen eines heilmittels
US20040073294A1 (en) 2002-09-20 2004-04-15 Conor Medsystems, Inc. Method and apparatus for loading a beneficial agent into an expandable medical device
AT500019B1 (de) * 2001-06-27 2007-06-15 Inst Gefaessbiologie Und Throm Verwendung in vitro des transkriptionsfaktors nak-1 oder von nak-1 regulierten genen zur diagnose von entzündlichen und malignen erkrankungen
GB0126389D0 (en) * 2001-11-02 2002-01-02 Pfizer Ltd Wafer
US7785653B2 (en) 2003-09-22 2010-08-31 Innovational Holdings Llc Method and apparatus for loading a beneficial agent into an expandable medical device
US7285530B2 (en) 2004-10-21 2007-10-23 Viron Therapeutics, Inc. Use of SERP-1 as an antiplatelet agent
US20090202524A1 (en) * 2007-10-31 2009-08-13 Alcon Research, Ltd. Pai-1 expression and activity inhibitors for the treatment of ocular disorders
WO2009093119A2 (en) * 2008-01-21 2009-07-30 Med Discovery S.A. Use of serine protease inhibitors in the treatment of skin diseases
CN109925507A (zh) * 2017-12-15 2019-06-25 深圳瑞健生命科学研究院有限公司 一种预防或治疗骨关节炎的方法和药物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3829523A1 (de) * 1988-08-31 1990-03-01 Behringwerke Ag Verwendung von plasminogen-aktivator-inhibitor (pai-2) zur immunsuppression
ES2106772T3 (es) * 1989-12-20 1997-11-16 Biotech Australia Pty Ltd Variantes de pai-2.
EP0451130A3 (en) * 1990-04-05 1992-08-05 Baltimore Biotech, Inc. Use of amiloride and other pyrazine derivatives for preventing or treating ocular neovascularization

Also Published As

Publication number Publication date
KR930021179A (ko) 1993-11-22
UY23572A1 (es) 1993-05-04
AU3822993A (en) 1993-11-04
IL105521A0 (en) 1993-08-18
CN1080873A (zh) 1994-01-19
ZA933023B (en) 1994-10-31
MX9302519A (es) 1993-10-01
NO931561D0 (no) 1993-04-29
JPH069425A (ja) 1994-01-18
HUT65755A (en) 1994-07-28
PL298748A1 (en) 1993-12-27
HU9301272D0 (en) 1993-07-28
CZ76893A3 (en) 1994-01-19
EP0567816A1 (de) 1993-11-03
DE4214215A1 (de) 1993-11-04
CA2095207A1 (en) 1993-10-31
NO931561L (no) 1993-11-01

Similar Documents

Publication Publication Date Title
SK41593A3 (en) Using of inhibitors of plasminogene activators for the production of medicament for a therapy of ignitions and wounds
EP1904108B1 (en) Ophthalmological formulation comprising methylsulfonylmethane and ciprofloxacin
AU2003297511B2 (en) Ophthalmic formulation for the prevention and treatment of ocular conditions
US7348306B2 (en) Composition for promoting lacrimal secretion
CN100558360C (zh) 羟胺组合物在制备缓解黄斑变性和其他眼科疾病的药物中的用途
US20060172972A1 (en) Formulation and method for administration of ophthalmologically active agents
WO2007011875A2 (en) Treatment of conditions associated with the presence of macromolecular aggregates, particularly ophthalmic disorders
US6610686B1 (en) Use of pirenoxine for the protection of corneal tissues in photokeractomy
KR20010040457A (ko) 안약 조성물
Kondo et al. Iontophoresis of 5-fluorouracil into the conjunctiva and sclera.
KR20010041337A (ko) 각막 상피 장애증 치료제
CA2515022A1 (en) Method for treating elevated intraocular pressure, including glaucoma
RU2284181C2 (ru) Фармацевтическая композиция для профилактики инфекции в офтальмологии "интрависк"
US8283323B2 (en) Withanolide compounds as inhibitors of fibrosis and identification of molecular targets for anti-fibrotic drug development
RU2423127C2 (ru) Терапевтическое средство против роговично-конъюнктивального нарушения
Almond et al. 5-Fluorouracil and Mitomycin-C
JPH0625005A (ja) 緑内障の治療に有用な薬剤の製造のためのｘ−ａｒｇ−ｇｌｙ−ａｓｐ−ｙの使用法
Gayre Medical management of thyroid eye disease
de ROETTH Ophthalmic pharmacology and toxicology
CZ20002770A3 (cs) Oční prostředky